Pro Medicus appoints Tim Reed: what it means for Pro Medicus stock

Published on 10/07/2026 at 04:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

FY2026 revenue rose 22.90 percent to AUD 261.70 million. That result frames Pro Medicus stock before its November 25 AGM.

Pro Medicus, AU000000PME8, Illustration mit AI erstellt.

Pro Medicus appoints Tim Reed as an independent non-executive director effective October 1, 2026, a board move that gives Pro Medicus stock a fresh governance angle. MarketScreener reported the appointment on September 23, 2026.

Tim Reed adds technology experience

Reed previously led MYOB as chief executive from 2008 to 2019 and brings experience in software, strategy, business development and investment. The appointment is effective as Pro Medicus expands a cloud-based medical imaging platform used by hospitals, imaging centers and healthcare groups across Australia, North America and Europe.

The board change does not alter the operating figures already available to investors. In fiscal year 2026, revenue rose 22.90 percent to AUD 261.70 million, while underlying net profit after tax increased 24.10 percent to AUD 144.70 million, according to Simply Wall St on August 19, 2026.

Profit growth exceeds revenue growth

Reported net income reached AUD 265.30 million in fiscal year 2026, up 130.30 percent from AUD 115.20 million in fiscal year 2025. The comparison with 22.90 percent revenue growth shows that reported profit expanded much faster than the top line, although the reported figure and underlying profit are different measures.

Fool Australia reported that Pro Medicus signed 10 new contracts worth AUD 407.00 million and renewed six contracts valued at AUD 141.00 million in fiscal year 2026. Those figures make contract conversion and implementation progress important measures for the next phase of growth.

AGM date adds the next milestone

Pro Medicus has scheduled its annual general meeting for November 25, 2026, according to Simply Wall St. The meeting gives shareholders a dated point for assessing governance, capital allocation and execution against the fiscal year 2026 results.

Pro Medicus shares are listed on the Australian Securities Exchange under PME. The company reported a final dividend of AUD 0.37 per share for the twelve months ended June 30, 2026, payable on September 29, 2026, as reported by Fool Australia.

Prior close remains the reference

The prior close at Lang & Schwarz was EUR 96.37 for October 5, 2026. Pro Medicus Limited has a market capitalization of AUD 16.7 billion and a 52-week range of AUD 107.75 to AUD 316.26 as of October 7, 2026. The further course of trading is shown by the continuously updated real-time quote of Pro Medicus stock.